Navigation Links
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
Date:5/13/2009

LAIYANG, China, May 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, Inc., OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:30 a.m. Eastern on Tuesday, May 19, 2009 to discuss financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.

Conference Call

The conference call will include Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO, and Ms. Elsa Sung, CFO, of Jiangbo Pharmaceuticals.

To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 481-7939. International callers should call (617) 847-8707. The Conference Passcode is 564 145 01.

If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, May 19, 2009 at 11:30 a.m. Eastern for fourteen days. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 547 268 69.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not h
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
2. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
3. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
9. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
10. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
11. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... PARSIPPANY, N.J., Dec. 7 Today the Centers ... of National Influenza Vaccination Week. While the week was ... also brings to light the importance of taking additional ... the peak cold and flu season of December, January ... all the information circulating around the topic of both ...
(Date:12/7/2009)... more emotional and behavioral difficulties when compared to other ... most when a parent is deployed overseas, according to ... having a parent deployed for a longer period of ... with emotional problems were important factors associated with whether ... published online by the journal Pediatrics . , ...
(Date:12/7/2009)... able to reverse some of the damage to their ... their cigarettes, according to research out of the University ... is published in the December 15 issue of the ... Critical Care Medicine . , "We found that exposure ... the epithelium, or lining, of the airways in the ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... NEW ORLEANSA drug that has become a mainstay ... in re-establishing the immune system of patients who ... matched donors, according to early clinical trial results ... Institute investigators at the American Society of Hematology,s ... 48, Ernest N. Morial Convention Center, Room 243-245, ...
Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2
... is thought to be resulted from a combination of ... specific genetic alterations. The pathogenesis and development of colorectal ... AF065388) is a new member of TM4SF located at ... protein. TSPAN1 was reported as a tumor-related gene recently. ...
... 22 Consorta, a leading healthcare group purchasing ... have received the Practice Greenhealth Champion for ... responsible healthcare. Consorta was presented the award at ... conjunction with CleanMed 2009, the premier Global Conference ...
... of Certified Organic Supplements, will be sold online and ... annual Herbal Supplement market!TUSTIN, Calif., May 22 On ... owned subsidiary of Zealous Inc. (OTC Bulletin Board: ZLUS) ... all natural herbal vitamins and supplements. These products, under ...
... FRAZER, Pa., May 22 Cephalon, Inc. (Nasdaq: ... its previously announced offering of $435 million in aggregate ... 2014 have exercised in full their over-allotment option to ... amount of the notes to be issued to $500 ...
... May 22 Ontario Systems, a leading provider ... for the debt management and health care industries, ... Cutler has joined the company and will lead ... for the strategic direction of all Ontario debt ...
... suggests loss of communication among cells tied to this ... -- Low levels of vitamin D may contribute to ... event in cancer is loss of communication among cells ... calcium levels," study leader Cedric Garland, an epidemiologist at ...
Other Medicine News:Health News:A novel marker of colorectal carcinoma 2Health News:Consorta Receives Practice Greenhealth Champion for Change Award for Sixth Consecutive Year 2Health News:Consorta Receives Practice Greenhealth Champion for Change Award for Sixth Consecutive Year 3Health News:Health and Wellness Partners, Inc., A Wholly Owned Subsidiary of Zealous Inc., Launches Organix+ 2Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 2Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 3Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 4Health News:Cutler to Direct Debt Management Product Strategy at Ontario Systems 2
(Date:12/6/2009)... -- Amgen Inc. (Nasdaq: AMGN ) today ... and efficacy of Nplate® (romiplostim) in adult patients ... condition in which early blood forming cells in ... thereby limiting their ability to produce normal mature ... counts. The results of the studies were presented ...
(Date:12/6/2009)... Bio Co., Ltd, ( www.rnl.co.kr ) a leading ... announced today that a 46-year-old female, Kang Sook ... cell treatment. Park was suffering from MS (Multiple ... nervous system (brain and spinal cord). ,, ... nerves of the central nervous system degenerate. MS ...
(Date:12/4/2009)... A simple, inexpensive computer tool that measures volume changes ... picked up by a CT scanner can rule out ... to diagnose true cancers with fewer, less expensive and ... The new diagnostic guidelines are described in a paper ...
Breaking Medicine Technology:Nplate(R) Data From MDS Studies Presented at ASH 2Nplate(R) Data From MDS Studies Presented at ASH 3Nplate(R) Data From MDS Studies Presented at ASH 4Nplate(R) Data From MDS Studies Presented at ASH 5Nplate(R) Data From MDS Studies Presented at ASH 6Nplate(R) Data From MDS Studies Presented at ASH 7Nplate(R) Data From MDS Studies Presented at ASH 8Nplate(R) Data From MDS Studies Presented at ASH 9Nplate(R) Data From MDS Studies Presented at ASH 10Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2When It Comes to Casual Sex Men Arent So Picky 54358 1When It Comes to Casual Sex Men Arent So Picky 54358 2Carnitine supplements reverse glucose intolerance in animals 9553 1Carnitine supplements reverse glucose intolerance in animals 9553 2A window into the brain 9551 1A window into the brain 9551 2
... BIRMINGHAM, Ala., April 03, 2007 /PRNewswire/ -- Southern,Research ... research in the areas of preclinical drug,discovery and ... delivering one oral presentation and 10 poster,presentations at ... Meeting, April 14-18 in Los Angeles, Calif. , ...
... Absorption of Fat and Protein during Clinical ... 04, 2007 /PRNewswire/ --,Eurand, a global specialty ... III clinical trials on its lead product,candidate, ... Pancreatic Insufficiency (EPI). The US Food and ...
Other Medicine Technology:Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
... and data management system ,RADIANCE is ... needs of data management systems (DMS), and ... of STAT analyzer systems., ,The RADIANCE software ... for both STAT analyzers and hospital and ...
... syngo Dynamics network is ... and archiving system using evidence-based ... of clinical procedures. It has ... practical reality for hospital echocardiography ...
... AXIOM Artis dTC is a versatile ... the cardiology department from preparation to ... interventional procedures. With AXIOM Artis dTC, your ... the cardiology department that leaves you free ...
... ACUSON Cypress cardiovascular system ... worlds first portable, high-performance transesophageal ... highly miniaturized, all-digital, phased array ... studies and outstanding images, even ...
Medicine Products: